Educational information, not medical advice — ask your doctor or midwife.
Talisadi Churna is a time-honored Ayurvedic compound powder first documented in classical texts including the Sharangadhara Samhita. It is built around Talisa patra — the bark and leaves of the Himalayan silver fir tree — combined with a synergistic blend of pungent and aromatic spices. The formula is considered Kapha-pacifying and Vata-balancing, making it particularly suited to respiratory and digestive conditions associated with excess mucus, coldness, and sluggishness.
The warm, pungent ingredients in Talisadi Churna — especially pippali, ginger, and black pepper — contain bioactive compounds like piperine and gingerols that support bronchodilation, stimulate digestive enzymes, and help liquefy and expel mucus from the airways. Cardamom and cinnamon add antimicrobial and carminative properties, while Vamshalochan (bamboo silica) provides a soothing, protective quality to irritated mucous membranes. Together these herbs create a warming, expectorant, and digestive-stimulating effect.
Traditional churna (fine herbal powder) is the classical preparation, typically taken with honey, warm water, or warm milk. Standardized tablets and capsules are widely available from Ayurvedic manufacturers and offer convenience, though practitioners consider the traditional powder form most effective for respiratory conditions.
Talisadi Churna is referenced in the Sharangadhara Samhita, a 13th-century Ayurvedic compendium, and has remained a front-line Ayurvedic remedy for respiratory and digestive complaints across South Asia for centuries. It is listed in the Ayurvedic Formulary of India, a government pharmacopoeia that standardizes classical formulations for modern clinical use.
Evidence grades and traditional-use labels are explained in our methodology. Nothing here is medical advice.
Reviewed by the HealisticMD editorial team How we grade evidence →
What it is typically used for, usual dose, cautions, and the study behind it where real trial data exists.
One email with the summary. We'll also send a short weekly evidence update — unsubscribe any time.